California Clinical Trials, PAREXEL International, Glendale, California, USA.
CNS Spectr. 2009 Aug;14(8 Suppl Q and A Forum):1-8.
Drug interactions with psychotropics can result in poor tolerability or reduced efficacy, or both, which can negatively impact patient outcomes. Most drug interactions with psychotropics are pharmacokinetic and involve the CYP family of enzymes. Clinicians can improve outcomes for patients by considering the potential for DDIs when selecting a specific psychotropic, and when evaluating patient progress, compliance, and the incidence of AEs throughout the course of treatment. Resources for clinicians include internet databases, software programs, package inserts, and consultation with pharmacists.
精神药物与药物的相互作用可导致耐受性差或疗效降低,或两者兼而有之,从而对患者的结局产生负面影响。大多数精神药物与药物的相互作用是药代动力学的,涉及 CYP 酶家族。临床医生可以通过在选择特定精神药物时考虑潜在的药物相互作用,以及在整个治疗过程中评估患者的进展、依从性和不良反应的发生率,来改善患者的结局。临床医生的资源包括互联网数据库、软件程序、说明书和与药剂师的咨询。